Click on image to view full bio
William Abraham, M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.E
Scientific Advisory Board Chair
Dr. William Abraham’s research interests include hemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation. Dr. Abraham has participated in all regulatory phases of new drug and device development from pre-clinical evaluation to Pre-Market Approval (PMA) and New Drug Application (NDA) submission and approval.
In addition to his role as Scientific Advisor for Cardionomic, Dr. Abraham also serves as Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at Ohio State University College of Medicine. He previously held faculty appointments at the University of Colorado, the University of Cincinnati, and the University of Kentucky. Dr. Abraham earned his medical degree from Harvard Medical School, and after that he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology at the University of Colorado Health Sciences Center. Board certified in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure and Transplant Cardiology, he spends the majority of his clinical time managing heart failure patients in the inpatient and outpatient settings.
Dr. Abraham is the author of more than 700 original papers, abstracts, book chapters, and review articles. He has also co-authored national heart failure practice guidelines and co-edited Heart Failure: A Practical Approach to Treatment, a leading textbook on heart failure. He continues to serve on the editorial boards of several major journals.
Ali Behbahani, M.D.
Dr. Behbahani is a Partner at NEA. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and health care services sectors.
Before joining NEA, he was an intern and business development consultant at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. Dr. Behbahani previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He also conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University.
Dr. Bahbahani graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. He concurrently earned his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar.
Chairman and CEO at Nevro
Michael DeMane is Executive Chairman of Nevro, a Silicon Valley-based leader in the medical device field. Michael led the company as CEO from March, 2011 until June, 2016, from scrappy start-up with negligible revenue to a leading global player in the spinal cord stimulation market. With an emphasis on the mechanics and culture of building the business, under his leadership the company raised two venture funding rounds totaling $106M, completed a $145M IPO (upsized and priced above the range), and subsequently initiated a public follow-on offering, again upsized to $260M.
An engineer by training, Mr. DeMane has established a consistent record of success leading both large and mid-size global med-tech organizations. Over the past 35 years, he has held executive leadership roles in the US, Europe and Australasia.
Prior to Nevro, Michael held a variety of positions at Medtronic, Inc., including: Chief Operating Officer, Sr. VP and President Europe, Canada, Latin America and Emerging Markets, and Sr. VP and President Spinal, ENT, and Navigation. In each of these roles he served on Medtronic’s Executive Committee.
Before joining Medtronic, Mr. DeMane served as Managing Director, Australasia for Smith & Nephew Pty. Ltd.
Michael has served as Senior Advisor to Thomas McNerney & Partners, and Oak Hill Capital. In addition he is on the Board of Directors of several firms in the medtech space including Cardionomic, Inc., Rotation Medical and SafeOrthopaedics.
Mr. DeMane has completed the Advanced Management Program at INSEAD in Fontainebleau, France and holds an M.S. in Bioengineering from Clemson University and a B.S in Chemistry from St. Lawrence University in Canton, New York.
Cardionomic President and CEO
Steve Goedeke’s extensive experience spans implantable defibrillators, pacemakers, therapies for heart failure, device design, and wireless communications.
Before joining Cardionomic as President and CEO, Goedeke was President and CEO at Denali Medical II and previously served as a Senior Director within Medtronic’s Cardiac Rhythm Disease Management division. He is a Bakken Fellow and was largely responsible for the creation of the MICS wireless system. He is also a two-time recipient of Medtronic’s Star of Excellence and was granted The Chairman’s Award for Outstanding Initiative. Before his 17 years at Medtronic, Goedeke held various technical and business development roles at Hewlett-Packard.
Goedeke is a named inventor on 25 patents and holds a B.S in electrical engineering from Washington University in St. Louis and a M.S. in electrical engineering from the University of Illinois at Urbana-Champaign.
Jon Heavey, M.D. MBA
Cleveland Clinic International Operations
Dr. Heavey contributes clinical and investment experience in his role with Cleveland Clinic Innovations and International Operations. He was selected as a Kauffman Fellow and helped serve as a liaison to chief clinical experts in the early stage development of Cardionomic technology. Currently, he is engaged in Cleveland Clinic’s emerging market and development team in operations throughout the Middle East. Prior to joining Cleveland Clinic he was an infantry battalion surgeon for the 101st Airborne Division in Iraq, where he earned a bronze star for his service. He is board certified in emergency medicine and holds a B.A. in Biomedical Engineering from Dartmouth College, an M.D. from Vanderbilt, and an M.B.A. from Yale University.
Anthony W. Borowicz
Vice President of Strategy & Development of Integer Holding Corp.
Mr. Borowicz is Vice President of Strategy & Development of Integer Holding Corp. Mr. Borowicz has worked in the medical device industry for 34 years. At Greatbatch, Mr. Borowicz is responsible for corporate strategy, mergers & acquisitions, technology licensing, venture investments and minority equity portfolio management. His previous roles at Integer, include VP of Finance for the QiG Group, & Treasurer and Director of Investor Relations. Prior to Greatbatch, Mr. Borowicz was VP Finance for Kendall Healthcare and Vice President & CFO for Graphics Controls. Mr. Borowicz currently serves on the Board of Directors at Cardionomic Inc.
Mr. Borowicz holds a Masters in Finance and Bachelor of Business Administration degree from Niagara University, NY. He is a Certified Management Accountant.
Tara Butler, M.D.
Managing Director, Ascension Ventures
Tara Butler came to Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several Ascension Ventures portfolio companies, including Apama Medical, Augmenix, CHF Solutions, Confluent Surgical, CSA Medical, EBR Systems, EKOS Corporation, HemoSphere, Ivantis, MindFrame, Neurolutions, Ocular Therapeutix (NASD:OCUL), Stereotaxis (NASD:STXS), and TomoTherapy (NASD:TOMO). Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell and as a laboratory research assistant at the University of Pennsylvania School of Medicine. She holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine.
CAUTION: INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.
©2016 Cardionomic, Inc. All Rights Reserved.